Compare Davita Inc (DVA) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Shopify Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Shopify Inc. trades at $165.07 (market cap $213.62B). The key difference: Shopify Inc. is far larger — about 18.9× Davita Inc's market cap, and Shopify Inc. is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Shopify Inc. for 78 Days on average.
| DVA | SHOP | |
|---|---|---|
Market Cap | $11.28B | $213.62B |
Volume | 650,294 | 6,320,766 |
Sector | Health | Technology |
52-Week High | $240.96 | $179.01 |
52-Week Low | $103.87 | $95.40 |
Typical Hold Time | 113 Days | 78 Days |
Enterprise Value | $24.00B | $208.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Shopify (SHOP) trades at $165.94, up 0.88% today, showing strong momentum near analyst consensus targets. The stock maintains a bullish technical outlook with solid fundamental growth - revenue increased from $5.6B in 2022 to $11.6B in 2025 while achieving profitability. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company continues to innovate with AI-powered commerce tools and expanding merchant solutions.
Shopify presents growth potential through e-commerce leadership and AI integration, though elevated valuation metrics (P/E 112, P/S 16) warrant caution. Key risks include competitive pressures from Amazon and valuation sensitivity to growth sustainability. Analyst consensus remains bullish with 67% buy ratings and $168.63 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
